Compositions and methods for detection of breast cancer
US-2024369558-A1 · Nov 7, 2024 · US
Use of the GTPase Rab27B to diagnose and treat poor prognosis estrogen-receptor-positive breast cancer
US9103833B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9103833-B2 |
| Application number | US-201013320729-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 12, 2010 |
| Priority date | May 15, 2009 |
| Publication date | Aug 11, 2015 |
| Grant date | Aug 11, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to evaluating the prognosis of patients with estrogen receptor-positive breast cancer on the basis of Rab27B expression. The invention further relates to a kit comprising an assay for measuring Rab27B levels in said patients and to the usage of Rab27B as a target to screen for drugs capable of inhibiting or diminishing metastasis of said cancer. Furthermore, the invention discloses compounds which can be used to treat estrogen receptor-positive breast cancer.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating a subject for poor prognosis estrogen receptor-positive breast cancer, the method comprising: treating a subject determined to be suffering from poor prognosis estrogen receptor-positive breast cancer by a diagnostic method comprising: determining the level of guanosine triphosphate hydrolaze Rat brain (Rab) 27B in a sample from the subject; comparing the level of Rab27B in the sample to a level of Rab27B in a control sample fro…
Assignees
Inventors
Classifications
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Physics · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9103833B2 cover?
- The present invention relates to evaluating the prognosis of patients with estrogen receptor-positive breast cancer on the basis of Rab27B expression. The invention further relates to a kit comprising an assay for measuring Rab27B levels in said patients and to the usage of Rab27B as a target to screen for drugs capable of inhibiting or diminishing metastasis of said cancer. Furthermore, the in…
- Who is the assignee on this patent?
- Wever Olivier De, Hendrix An, Westbroek Wendy, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification G01N33/57515. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Aug 11 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).